Cyprotex wins US government contract

Published: 1-May-2013
Manufacturing Research & Development Finance

Will provide high content imaging analysis for EPA ToxCast Project


Cyprotex, a UK headquartered specialist preclinical contract research organisation, has won a five-year contract with the US Environmental Protection Agency (EPA).

The Macclesfield, Cheshire-based firm will be working on the EPA’s ongoing ToxCast Project testing the environmental impact of chemicals. Cyprotex will be providing high content imaging bioassay analysis of the ToxCast Compound Library.

No financial details have been revealed.

Chief Executive Tony Baxter said a previous delay in the signing of the high content toxicology deal had hit first-half sales to 31 December 2012 in the US, which fell by 12% for the AIM-listed firm.

Sales growth is expected to accelerate in the second half of the year.

  • Companies:
  • Cyprotex
See more

You may also like

Research & Development

Cyprotex acquires CeeTox

Read more
Broadens toxicological assay and screening capabilities

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  5. Automate LC purification & high-purity compound recovery with UFPLC The purification instrument allows manufacturers to extract high-purity compounds in a shorter timeframe

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Research & Development

Cyprotex acquires CeeTox

Broadens toxicological assay and screening capabilities
Research & Development

Cyprotex to expand its UK facility into BioHub at Alderley Park

Will provide additional capacity for laboratories and office space
Research & Development

Cyprotex reports good performance across all parts of the business in first half

Gains new investors and raises £7m in cash to be used for further investment in the US and to assist with acquisitions
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Interview: Medicines and meteorites

ADME-Tox, good quality medicines and meteorites are three things that Tony Baxter, CEO of Cyprotex in Macclesfield, UK and Boston, US is keen on. He tells Jane Ellis why
Research & Development

Cyprotex launches eCiphrCardio cardiotoxicity service

To assess compounds in early drug development
Research & Development

Cyprotex subsidiary to take part in research project with Pfizer

To develop and improve offerings in the area of predictive toxicology
Research & Development

Cyprotex to expand Boston, US facility

Driven by strong demand for the specialist in vitro toxicology services offered at the facility
Subscribe now